Media coverage about Editas Medicine (NASDAQ:EDIT) has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Editas Medicine earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.5017465825622 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of brokerages recently commented on EDIT. Zacks Investment Research lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Cowen reiterated a “buy” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. BidaskClub lowered Editas Medicine from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. ValuEngine lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $28.00 target price (up previously from $27.00) on shares of Editas Medicine in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $26.73.
Editas Medicine (EDIT) opened at $30.40 on Friday. Editas Medicine has a twelve month low of $13.12 and a twelve month high of $36.00. The stock has a market capitalization of $1,370.00 and a P/E ratio of -9.38. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12.
In other Editas Medicine news, insider Katrine Bosley sold 8,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $23.64, for a total value of $196,992.12. Following the completion of the transaction, the insider now directly owns 1,393,322 shares of the company’s stock, valued at $32,938,132.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew A. F. Hack sold 14,649 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $24.68, for a total value of $361,537.32. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $123,400. The disclosure for this sale can be found here. Insiders sold 61,310 shares of company stock valued at $1,689,449 over the last three months. 19.40% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Editas Medicine (EDIT) Earns News Sentiment Score of 0.07” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://stocknewstimes.com/2018/01/20/editas-medicine-edit-earns-news-sentiment-score-of-0-07.html.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.